---
title: Non-Invasive Monitoring Non-alcoholic Steatohepatitis
description: "Download this whitepaper to discover an assay that can:\n\nIdentify biomarkers for susceptibility to NASH\nReliably predict hepatic fat accumulation\nHelp to predict the success of interventions in particular patient subpopulations"
image: https://go.technologynetworks.com/hubfs/Technology%20Networks/TN%20Editorial%20Calendar/Article/SomaLogic%20-%20Article%20Sponsorship/smartmockups_l1dqcobl.png
---

![BlueTwoLine](https://go.technologynetworks.com/hs-fs/hubfs/Technology%20Networks/Logos/BlueTwoLine.png?width=678&name=BlueTwoLine.png "BlueTwoLine")

![TN_Stacked_White-1](https://go.technologynetworks.com/hubfs/Imported%20images/TN_Stacked_White-1.png "TN_Stacked_White-1")

![TN_Stacked_White-1](https://go.technologynetworks.com/hubfs/Imported%20images/TN_Stacked_White-1.png "TN_Stacked_White-1")

Whitepaper

# Non-Invasive Monitoring of Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD), a liver condition that is characterized by liver steatosis accompanied by liver cell injury and inflammation.

Diagnosing the severity of NAFLD and NASH heavily relies on liver biopsy. While histological examination of the liver allows for precise diagnosis, it can cause abdominal discomfort and bleeding and may not be able to provide unbiased diagnosis if only a small section of hepatic tissue is analyzed. Because different components of liver pathology of NASH are characterized by distinct sets of protein signatures, non-invasive proteomic-based screening can now be used to detect these signatures and diagnose NASH.

Download this whitepaper to discover an assay that can:

- Identify biomarkers for susceptibility to NASH
- Reliably predict hepatic fat accumulation
- Help to predict the success of interventions in particular patient subpopulations

**Brought to you by:**

 

**![MicrosoftTeams-image (3)](https://go.technologynetworks.com/hs-fs/hubfs/Technology%20Networks/Landing%20Pages/Soma%20Logic/MicrosoftTeams-image%20(3).png?width=180&name=MicrosoftTeams-image%20(3).png)**

 

  
**Download this whitepaper to discover an assay that can:**

- Identify biomarkers for susceptibility to NASH
- Reliably predict hepatic fat accumulation
- Help to predict the success of interventions in particular patient subpopulations

Access this Whitepaper for FREE Now!

![TN_Stacked](https://go.technologynetworks.com/hubfs/Imported%20images/TN_Stacked.svg "TN_Stacked")

Technology Networks Limited   
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK   
Email: privacy@technologynetworks.com   
© 2022 Technology Networks. All rights reserved

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our [Privacy Policy](https://www.technologynetworks.com/tn/privacy)

This content is copyright protected. Any public or private use of this content is subject to prevailing copyright laws. Please contact [Technology Networks](https://www.technologynetworks.com/tn/copyright) for permission requests.